Transfusion-transmitted HIV from seroconverted blood donors has not been identified in England since the introduction of HIV NAT screening

Size: px
Start display at page:

Download "Transfusion-transmitted HIV from seroconverted blood donors has not been identified in England since the introduction of HIV NAT screening"

Transcription

1 Transfusion-transmitted HIV from seroconverted blood donors has not been identified in England since the introduction of HIV NAT screening Bhavita Vishram

2 Timeline of introduction of microbiological tests for blood donations, UK

3 Window period Developed from Schriber et al NEJM 1996 by Soldan et al Vox Sang 2003; Eurosurveillance 2005

4 The current risk of not detecting an HIV infectious donation is much less than 1 per million donations.

5 Lookback investigations I HIV positive repeat blood donor most recent previous negative donation (MRPD) possibility that previous donation was infectious but not detected donated in window period or false negative. lookback testing archives, tracing fate of components made from MRPD and arranging notification of living recipients. introduction of NAT screening and Ab/Ag assays reduced chance of false negative.

6 Lookback investigations II positive repeat donor donor contacted and offered a post test discussion with a NHSBT clinician. stored archive sample (kept for 3 years) tested in an individual sample HIV PCR test. irrespective of the result, a lookback is often carried out to determine fate of blood components. lookback may not be carried out where other information points to the infection having being acquired a later date. clear history of seroconversion illness credible risk for infection in the donor with postdates the MRPD. the results of all lookbacks are collated by the NHSBT/PHE Epidemiology unit.

7 Case 1 male donor - late 20 s donation in November previous donation March 2016 avidity seroconversion may have occurred within 4 months of donation archive sample HIV PCR negative. history of new female partner after MRPD seroconversion illness in June with high fever, diarrhoea, vomiting and night sweats. NO LOOKBACK CONDUCTED

8 Case 2 male - Mid 40 s donation in January previous donation September one off sexual contact with another male no clear history archive sample was HIV PCR negative LOOKBACK CONDUCTED Red cells transfused - recipient identified, tested HIV negative Platelets transfused recipient identified deceased before lookback conducted

9 Where archive samples test negative on singleton PCR do we need to continue HIV lookback investigations?

10 Data from 1995 to 2008

11 Data from 1995 to 2008 Byrne et al Transfusion

12 Data from 2009 to 2016

13 Results archive samples 65 HIV positive repeat donors 60 seroconverted within 3 years 53 archive samples tested negative 7 3 archive samples unavailable 4 archives not tested due to donor history and avidity showing recent infection

14 Results lookback investigations 33 lookback investigations 32 recipients 10 deceased 18 tested HIV negative 4 outcome unknown NO HIV TRANSMISSIONS WERE IDENTIFIED

15 since the introduction of pooled HIV NAT screening in 2003: 4 HIV window period donations (NAT pick ups) detected by screening; negative on HIV serology but reactive on pooled HIV NAT screening. no cases of HIV transmission detected by lookback investigations since routine NAT screening was introduced within NHSBT.

16 Where archive samples test negative on singleton PCR do we need to continue HIV lookback investigations?

17 NHSBT governance committee recently approved no lookback is needed where archive samples test HIV PCR negative.

18 Conclusion HIV screening has improved in sensitivity over the last 20 years. 4 window period donations have been detected through screening of 21 million donations from number of window period donations not detected through the use of pooled HIV NAT screening will be vanishingly small and lookback has failed to detect any. discontinue lookback investigations where archive samples HIV PCR negative.

19 Acknowledgements Dr Patricia Hewitt Dr Su Brailsford Claire Reynolds Katy Davison All staff in hospitals who have helped in collecting information.

Playing Detective: going in search of the source of infection. Su Brailsford Consultant in Epidemiology and Health Protection

Playing Detective: going in search of the source of infection. Su Brailsford Consultant in Epidemiology and Health Protection Playing Detective: going in search of the source of infection Su Brailsford Consultant in Epidemiology and Health Protection The Micro Services clinical team Are inquisitive Like problem solving Don t

More information

Hepatitis E and the English blood supply

Hepatitis E and the English blood supply Hepatitis E and the English blood supply Mhairi Webster Microbiology Senior Scientist National Transfusion Microbiology Reference Laboratory With thanks to Dr Alan Kitchen Hepatitis E virus Small, non-enveloped

More information

Lookback studies to assess viral risks The French experience

Lookback studies to assess viral risks The French experience Lookback studies to assess viral risks The French experience 2000-2012 S Laperche 1, MF Leconte des Floris 2, J Pillonel 3, L Hauser 2, C Lefort 2, JY Py 2, I Hervé 2, R Djoudi 2 For the French haemovigilance

More information

Impact of changing donor demographics on HIV transmission risk: A ten year analysis of individual donation NAT screening

Impact of changing donor demographics on HIV transmission risk: A ten year analysis of individual donation NAT screening Impact of changing donor demographics on HIV transmission risk: A ten year analysis of individual donation NAT screening IPFA Lisbon 216 Marion Vermeulen Disclaimer Race classifications are described as

More information

TRANSFUSION ASSOCIATED DISEASE, RECALL, OR COMPLICATION INVESTIGATION POLICY I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION:

TRANSFUSION ASSOCIATED DISEASE, RECALL, OR COMPLICATION INVESTIGATION POLICY I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION: I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION: A. TRANSFUSION RELATED FATALITY: FDA and MEDIC must be notified immediately, and subsequently in writing, when a possible transfusion related

More information

Annual SHOT Report 2016 Supplementary Information. Chapter 17: Transfusion-Transmitted Infections (TTI)

Annual SHOT Report 2016 Supplementary Information. Chapter 17: Transfusion-Transmitted Infections (TTI) Annual SHOT Report 2016 Supplementary Information Chapter 17: Transfusion-Transmitted s (TTI) The table below is an excerpt from the full Table 17.3 which can be viewed in the main report. Case reports

More information

Chapter 17: Transfusion-Transmitted Infections (TTI)

Chapter 17: Transfusion-Transmitted Infections (TTI) Annual SHOT Report 2014 Supplementary Information Chapter 17: Transfusion-Transmitted s (TTI) The table below is an excerpt from the full Table 17.2 which can be viewed in the main report. Case reports

More information

Transfusion-transmitted Cytomegalovirus

Transfusion-transmitted Cytomegalovirus Transfusion-transmitted Cytomegalovirus Can you confidently abandon CMV seronegative products in the modern era of pre-storage leukoreduction? Jeannie Callum, BA, MD, FRCPC Really? Are we still talking

More information

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations Jackson B R, Busch M P, Stramer S L, AuBuchon J P Record Status This is a critical abstract of an economic evaluation that meets

More information

CTYOMEGALOVIRUS (CMV) - BACKGROUND

CTYOMEGALOVIRUS (CMV) - BACKGROUND CTYOMEGALOVIRUS (CMV) - BACKGROUND PURPOSE The flowing information provides guidance on the use of CMV negative blood components provided by the blood bank at the Royal Children s Hospital (RCH) including

More information

risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV)

risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV) Prevention and ResidualR risk of Transfusion-Transmitted Transmitted Viral Infections (HIV, HCV and HBV) Syria Laperche L (Centre National de référence r rence pour les hépatites h B et C en Transfusion)

More information

2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies

2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies 2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies Submitted by: Malaysia Policy Dialogue and Workshop on Attaining a Safe and Sustainable Blood Supply Chain Manila, Philippines 30 September 1

More information

Screening donors and donations for transfusion transmissible infectious agents. Alan Kitchen

Screening donors and donations for transfusion transmissible infectious agents. Alan Kitchen Screening donors and donations for transfusion transmissible infectious agents Alan Kitchen Aim Not to teach you microbiology To provide and awareness of the big picture To provide an understanding of

More information

Impact of multi-dye multiplex technology on testing algorithm

Impact of multi-dye multiplex technology on testing algorithm Impact of multi-dye multiplex technology on testing algorithm Lydia Blanco. Mª Isabel Gonzalez-Fraile Centro de Hemoterapia y Hemodonación de Castilla y León, España TTI EPIDEMIOLOGICAL DATA IN SPAIN NAT

More information

Surveillance Report 2014

Surveillance Report 2014 Surveillance Report 2014 Executive summary We are pleased to present the third report for our stakeholders describing infectious disease surveillance. High quality and timely surveillance is key to the

More information

Public Health, Infections and Transplantation

Public Health, Infections and Transplantation Public Health, Infections and Transplantation Dr Kerry Chant Chief Health Officer & Deputy Director General Population and Public Health NSW Ministry of Health May2014 Public Health Infection and Transplantation

More information

Infectious Disease Considerations in Organ Donation. Nikole A Neidlinger MD FACS Chief Medical Officer

Infectious Disease Considerations in Organ Donation. Nikole A Neidlinger MD FACS Chief Medical Officer Infectious Disease Considerations in Organ Donation Nikole A Neidlinger MD FACS Chief Medical Officer Screening Donors and Infectious Disease considerations: Deceased Donor Screening Donors at increased

More information

New recommendations for immunocompromised patients

New recommendations for immunocompromised patients New recommendations for immunocompromised patients Hepatitis E Virus (HEV): Transmission, incidence and presentation Emerging evidence regarding HEV transmission from blood components and dietary consumption

More information

Anticipating (re)emerging infections to ensure blood safety

Anticipating (re)emerging infections to ensure blood safety Anticipating (re)emerging infections to ensure blood safety Pierre Tiberghien Etablissement Français du Sang, St-Denis and Université de Franche-Comté, Besançon, France IPFA/PEI 23rd International Workshop

More information

Guide to the preparation, use and quality assurance of blood components

Guide to the preparation, use and quality assurance of blood components Contents Foreword...3 Members of the European Committee (Partial Agreement) on Blood Transfusion... 8 Members of the GTS working group... 22 Members of the TS066 working group... 30 Recommendation No.

More information

The testing of Donated Blood and Components at NHSBT

The testing of Donated Blood and Components at NHSBT The testing of Donated Blood and Components at NHSBT NHSBT is responsible for collecting all donated blood and platelets in England, then processing into components before issuing to client hospitals.

More information

July 14, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

July 14, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852 July 14, 2015 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Submitted via http://www.regulations.gov Re: Docket No. FDA-2015-D-1211

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components (including Source Plasma and Source Leukocytes) to Adequately and Appropriately

More information

Change in deferrals for men who have sex with men: Assessing the risk of HIV transmission by transfusion

Change in deferrals for men who have sex with men: Assessing the risk of HIV transmission by transfusion Change in deferrals for men who have sex with men: Assessing the risk of HIV transmission by transfusion Josiane Pillonel, Rachid Djoudi, Florence Lot, Chistophe Martinaud, Claire Sauvage, Marie Jauffret-Roustide,

More information

Transfusion Risk for Hepatitis B, Hepatitis C and HIV in the State of Santa Catarina, Brazil,

Transfusion Risk for Hepatitis B, Hepatitis C and HIV in the State of Santa Catarina, Brazil, 236 BJID 2004; 8 (June) Transfusion Risk for Hepatitis B, Hepatitis C and HIV in the State of Santa Catarina, Brazil, 1991-2001 Emil Kupek Department of Public Health, Federal University of Santa Catarina,

More information

June 8, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

June 8, Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852 June 8, 2018 Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Submitted via http://www.regulations.gov Re: Docket No. FDA 2016 D 0545,

More information

Surveillance Report 2016

Surveillance Report 2016 Surveillance Report 2016 Executive summary We are pleased to present the fifth report for our stakeholders describing infectious disease surveillance. High quality and timely surveillance is key to the

More information

HEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38

HEPATITIS C, ACUTE CRUDE DATA. Number of Cases 5 Annual Incidence a LA County 0.05 California b 0.10 United States b 0.68 Age at Diagnosis Mean 38 2016 Annual Morbidity Report HEPATITIS C, ACUTE a Rates calculated based on less than 19 cases or events are considered unreliable b Calculated from: CDC. Notice to Readers: Final 2016 Reports of Nationally

More information

Surveillance Report 2015

Surveillance Report 2015 Surveillance Report 2015 Executive summary We are pleased to present the fourth report for our stakeholders describing infectious disease surveillance. High quality and timely surveillance is key to the

More information

Impact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013

Impact of Testing Strategies to Reduce Transmission Risk for HBV. Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Impact of Testing Strategies to Reduce Transmission Risk for HBV Ravi Reddy, M Vermeulen South African National Blood Service (SANBS) 29 July 2013 Overview of SANBS SANBS is a private not for profit company

More information

Congenital CMV infection. Infectious and Tropical Pediatric Division Department of Child Health Medical Faculty, University of Sumatera Utara

Congenital CMV infection. Infectious and Tropical Pediatric Division Department of Child Health Medical Faculty, University of Sumatera Utara Congenital CMV infection Infectious and Tropical Pediatric Division Department of Child Health Medical Faculty, University of Sumatera Utara Congenital CMV infection Approximately 0.15 2% of live births

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT. APPENDICES a TO GUIDELINE ON EPIDEMIOLOGICAL DATA ON BLOOD TRANSMISSIBLE INFECTIONS

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT. APPENDICES a TO GUIDELINE ON EPIDEMIOLOGICAL DATA ON BLOOD TRANSMISSIBLE INFECTIONS European Medicines Agency Evaluation of Medicines for Human Use London, 20 May 2009 Doc. Ref. EMEA/CPMP/BWP/125/04 Rev.1 Appendices COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT APPENDICES

More information

BACTERIAL INTERVENTIONS TO INCREASE BLOOD SAFETY

BACTERIAL INTERVENTIONS TO INCREASE BLOOD SAFETY BACTERIAL INTERVENTIONS TO INCREASE BLOOD SAFETY Jennifer Allen National Bacteriology Laboratory on behalf of Dr. C P McDonald Head of Bacteriology National Bacteriology Laboratory NHSBT Klebsiella oxytoca

More information

WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA

WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 21 October 2016 WHO GUIDELINES ON ESTIMATION OF RESIDUAL RISK OF HIV, HBV OR HCV INFECTIONS VIA CELLULAR BLOOD COMPONENTS AND PLASMA

More information

R Offergeld, D Faensen, S Ritter, O Hamouda Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany

R Offergeld, D Faensen, S Ritter, O Hamouda Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany Eurosurveillance, Volume 10, Issue 2, 01 February 2005 Surveillance report HUMAN IMMUNODEFICIENCY VIRUS, HEPATITIS C AND HEPATITIS B INFECTIONS AMONG BLOOD DONORS IN GERMANY 2000-2002: RISK OF VIRUS TRANSMISSION

More information

ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S.

ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S. ARCHITECT HIV Ag/Ab Combo: Moving HIV Diagnostics Forward in the U.S. Catherine Brennan, Ph.D. Research Fellow Infectious Diseases Research Abbott Diagnostics 1 Agenda ARCHITECT HIV Ag/Ab Combo Assay What

More information

Source Plasma Safety

Source Plasma Safety Source Plasma Safety Plasma May 15-19, 2017 George Schreiber, ScD, PPTA Director, Epidemiology Three components: Plasma Product Safety Donor Quality Manufacturing Pool Quality Fractionation Process Safe

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Revised Recommendations for Donor and Product Management Based on Screening Tests for Syphilis DRAFT GUIDANCE This document is being distributed for comment purposes only. Submit

More information

Dengue Fever & Dengue Hemorrhagic Fever Annual Reports to WHO

Dengue Fever & Dengue Hemorrhagic Fever Annual Reports to WHO Dengue Virus Member of the genus Flavivirus Transmitted by the Aedes mosquito; mosquito => human cycle 4 serotypes: DENV1, 2, 3, and 4 Homotypic immunity is long lasting Heterotypic immunity is short lived

More information

AdvaMedDx Value Assessment Framework in Practice

AdvaMedDx Value Assessment Framework in Practice AdvaMedDx Value Assessment Framework in Practice Application of the Comprehensive Assessment of the Value of Diagnostic Technologies Framework to Abbott s 4th Generation ARCHITECT HIV Antigen/Antibody

More information

RISK OF DISEASE TRANSMISSION FROM ORGAN DONORS PATIENT INFORMATION GUIDE

RISK OF DISEASE TRANSMISSION FROM ORGAN DONORS PATIENT INFORMATION GUIDE Receiving an organ transplant carries many risks, including the risk of getting a disease from the June 2017 donor. This is true for every organ we transplant. BC Transplant makes every effort to minimize

More information

Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India.

Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India. Frequency of occult hepatitis B in HBsAg seronegative blood donors in a tertiary care hospital in kerala,south India. Cinzia Keechilot, Veena Shenoy 1,V Anil kumar 2,Lalita Biswas 3. MBBS student * Transfusion

More information

Copyright, 1995, by the Massachusetts Medical Society

Copyright, 1995, by the Massachusetts Medical Society Copyright, 1995, by the Massachusetts Medical Society Volume 333 DECEMBER 28, 1995 Number 26 ESTIMATED RISK OF TRANSMISSION OF THE HUMAN IMMUNODEFICIENCY VIRUS BY SCREENED BLOOD IN THE UNITED STATES EVE

More information

transfusion-transmissible HCV and HIV in Italy Haemovigilance and the residual risk of

transfusion-transmissible HCV and HIV in Italy Haemovigilance and the residual risk of Haemovigilance and the residual risk of transfusion-transmissible Giuliano Grazzini, MD National Blood Centre, National Institute of Health, Rome, Italy & International Federation of Blood Donor Organizations

More information

Hepatitis C Best Practice Guidelines For Local Health Departments

Hepatitis C Best Practice Guidelines For Local Health Departments Hepatitis C Best Practice Guidelines For Local Health Departments LHDs are responsible for investigating and reporting all physician reported cases of acute hepatitis C (HCV). For clients known to have

More information

Non-reproductive tissues and cells Recommending authority/ association

Non-reproductive tissues and cells Recommending authority/ association Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent - legy binding More stringent - recommended Not legy binding and not recommended Tested pathogen Donor test/ technique

More information

Test Name Results Units Bio. Ref. Interval

Test Name Results Units Bio. Ref. Interval LL - LL-ROHINI (NATIONAL REFERENCE 135091606 Age 24 Years Gender Male 30/8/2017 92800AM 30/8/2017 94631AM 31/8/2017 90306AM Ref By Final HEATITIS A & B VIRUS EVALUATION HEATITIS A ANTIBODY (ANTI HAV),

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Lookback for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test

More information

The Alphabet Soup of Viral Hepatitis Testing

The Alphabet Soup of Viral Hepatitis Testing The Alphabet Soup of Viral Hepatitis Testing August 18, 2011 Patricia Slev, PhD, DABCC Medical Director, Serologic Hepatitis and Retrovirus Laboratory, ARUP Laboratories Assistant Professor of Pathology,

More information

NAT Screening of Blood Donations in NBC, TRCS

NAT Screening of Blood Donations in NBC, TRCS IPFA/PEI, Italy NAT Screening of Blood Donations in NBC, TRCS 2000-2001 Clinical evaluation using COBAS AmpliiScreen HIV & HCV assays, (MP24) window period rate - 1 : 108,768 for HIV-1 and HCV 2002 Routine

More information

The Immune Response to Parvovirus B19 Exposure in Previously Seronegative and Seropositive Individuals

The Immune Response to Parvovirus B19 Exposure in Previously Seronegative and Seropositive Individuals BRIEF REPORT The Immune Response to Parvovirus B19 Exposure in Previously Seronegative and Seropositive Individuals Sean Doyle and Amanda Corcoran a Department of Biology and National Institute for Cellular

More information

HEV Update Blood Components. Dragoslav Domanović, European Centre for Disease Prevention and Control (Sweden)

HEV Update Blood Components. Dragoslav Domanović, European Centre for Disease Prevention and Control (Sweden) HEV Update Blood Components Dragoslav Domanović, European Centre for Disease Prevention and Control (Sweden) Outline ECDC activities started in 2015 to understand the epidemiology and burden of HEV infection

More information

Patient Name: MRN: DOB: Treatment Location:

Patient Name: MRN: DOB: Treatment Location: Page 1 of 5 I. TO (Required) This Section is required to be completed by all patients who undergo kidney transplant surgery. I hereby consent to and authorize Dr. and his/her assistant(s), including supervised

More information

Adverse Reactions Associated with Methylene Blue Inactivated Fresh Frozen Plasma (MB FFP)

Adverse Reactions Associated with Methylene Blue Inactivated Fresh Frozen Plasma (MB FFP) Adverse Reactions Associated with Methylene Blue Inactivated Fresh Frozen Plasma (MB FFP) Constantina Politis Hellenic Coordinating Haemovigilance Centre (SKAE) Background Pathogen inactivation is expected

More information

Pandemic Flu, MERS-CoV, Ebola! What's next? What are we doing about emerging infections?

Pandemic Flu, MERS-CoV, Ebola! What's next? What are we doing about emerging infections? Pandemic Flu, MERS-CoV, Ebola! What's next? What are we doing about emerging infections? BBTS 2014 Claire Reynolds, Scientist NHS Blood and Transplant / Public Health England Epidemiology Unit Pandemic

More information

What You Need to Know About Blood Transfusion. Elianna Saidenberg May 2014

What You Need to Know About Blood Transfusion. Elianna Saidenberg May 2014 What You Need to Know About Blood Transfusion Elianna Saidenberg May 2014 Objectives Why your doctor might order transfusion therapy Where does the blood come from The beginning of your transfusion Consent

More information

Hot Topics in Tissue Safety

Hot Topics in Tissue Safety Hot Topics in Tissue Safety 37 th Annual AATB Meeting National Harbor, Maryland 03 October 2013 Scott A. Brubaker, CTBS Chief Policy Officer PHS Guideline for Reducing Human Immunodeficiency Virus, Hepatitis

More information

Laboratory reports of hepatitis A and C infection in England and Wales: January to March

Laboratory reports of hepatitis A and C infection in England and Wales: January to March Volume 4 29 Published on: 23 July 2010 Current News Increased diagnoses of HIV infection in the over-50s in UK Infection Reports Immunisation Laboratory reports of hepatitis A and C infection in England

More information

HIV and AIDS. Lesson. By Carone Fitness. HIV and AIDS

HIV and AIDS. Lesson. By Carone Fitness. HIV and AIDS Lesson By Carone Fitness The leading cause of death for people between the ages of 25-44 is Acquired Immune Deficiency Syndrome (AIDS). AIDS is the final stage of an HIV infection that is characterized

More information

Consent and donor choice in lung and heart-lung transplantation

Consent and donor choice in lung and heart-lung transplantation Consent and donor choice in lung and heart-lung transplantation A patient s guide 1 Lung transplantation is a good option for carefully selected patients with end stage lung disease but sadly there is

More information

DENGUE AND BLOOD SAFETY. Ester C Sabino, MD, PhD Dep. of Infectious Disease/Institute of Tropical Medicine University of São Paulo

DENGUE AND BLOOD SAFETY. Ester C Sabino, MD, PhD Dep. of Infectious Disease/Institute of Tropical Medicine University of São Paulo DENGUE AND BLOOD SAFETY Ester C Sabino, MD, PhD Dep. of Infectious Disease/Institute of Tropical Medicine University of São Paulo Dengue virus Arbovirus (arthropod-borne virus) virus transmitted by mosquitoes:

More information

Commonly Asked Questions About Chronic Hepatitis C

Commonly Asked Questions About Chronic Hepatitis C Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral

More information

your liver Care for Think about hepatitis

your liver Care for Think about hepatitis your liver Care for Think about hepatitis World Hepatitis Day 2015 What is hepatitis? Hepatitis is the common name for all inflammatory diseases of the liver. Liver inflammation is most often caused by

More information

CHART ELEVEN (11) KENYAN FIGURES (KENYA DEMOGRAPHIC HEALTH SURVEY REVISED 2004)

CHART ELEVEN (11) KENYAN FIGURES (KENYA DEMOGRAPHIC HEALTH SURVEY REVISED 2004) CHART ELEVEN (11) KENYAN FIGURES (KENYA DEMOGRAPHIC HEALTH SURVEY REVISED 2004) Adults living with HIV/AIDS - 1.1 million Children - 150,000 Number using ART - 24,000 Number needing ARVs - 200,000 National

More information

Malaria screening of donors and donations - issues and outcomes

Malaria screening of donors and donations - issues and outcomes Malaria screening of donors and donations - issues and outcomes lan Kitchen National Transfusion Microbiology NHS Blood & Transplant London IPF/PEI, Rome, May 2014 Blood and Transplant Key elements Nature

More information

Overview of Blood Transfusion System of Iran:

Overview of Blood Transfusion System of Iran: Report Article Overview of Blood Transfusion System of Iran: 2002-2011 AM Cheraghali High Institute for Research and Education on Transfusion Medicine, Iran Blood Transfusion Organization and University

More information

What is HIV? An educational booklet supported by:

What is HIV? An educational booklet supported by: What is HIV? An educational booklet supported by: Contents 1. A message from Marieanne Spacey 2. HIV in the UK 3. What is HIV? 4. What is AIDS? 5. How is HIV transmitted? 6. You CAN T catch HIV by... 7.

More information

Instruction to implement measures for risk minimisation in using HIV-1 NAT test systems

Instruction to implement measures for risk minimisation in using HIV-1 NAT test systems Paul-Ehrlich-Institut P.O. Box 63207 Langen, Germany To: The marketing authorisation holders of cellular blood products and fresh frozen plasma and the holders of authorisations for stem cell preparations

More information

[Submitted Electronically]

[Submitted Electronically] [Submitted Electronically] Dr. Matthew J. Kuehnert, Director Office of Blood, Organ, and Other Tissue Safety Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic Infectious

More information

An Audit of Emergency Group O blood use in Royal Devon and Exeter Hospital

An Audit of Emergency Group O blood use in Royal Devon and Exeter Hospital An Audit of Emergency Group O blood use in Royal Devon and Exeter Hospital Jack Cunningham Keira Soanes Why are we looking at our use of Emergency Group O RhD negative blood? Following the NHSBT National

More information

BLOOD DONATION OR BLOOD DONOR DEFERRAL BASED ON DATA ON NONCONFORMITIES DETECTED IN POST-SELECTION PERIOD (DURING AND AFTER BLOOD COLLECTION)

BLOOD DONATION OR BLOOD DONOR DEFERRAL BASED ON DATA ON NONCONFORMITIES DETECTED IN POST-SELECTION PERIOD (DURING AND AFTER BLOOD COLLECTION) BLOOD DONATION OR BLOOD DONOR DEFERRAL BASED ON DATA ON NONCONFORMITIES DETECTED IN POST-SELECTION PERIOD (DURING AND AFTER BLOOD COLLECTION) Tomislav Vuk Croatian Institute of Transfusion Medicine Zagreb

More information

The how and why of Acute HIV Infection 1. How do we best diagnosis patients with acute HIV?

The how and why of Acute HIV Infection 1. How do we best diagnosis patients with acute HIV? Acute HIV infection Eric Rosenberg, MD Associate Professor of Pathology Director, Clinical Microbiology Laboratory Massachusetts General Hospital Harvard Medical School The how and why of Acute HIV Infection

More information

HLA Selected Platelets

HLA Selected Platelets HLA Selected Platelets Dr PhD Clinical Scientist Department of Histocompatibility & Immunogenetics NHS Blood and Transplant Colindale Poor increment (

More information

Plasma for fractionation: South African Plasma Requirements

Plasma for fractionation: South African Plasma Requirements Plasma for fractionation: South African Plasma Requirements Dr Jeh-han Omarjee Head: Microbiological Sciences NBI is a "not for profit" company committed to providing safe, cost effective, quality medicinal

More information

Khalid Alquthami (Correspondence) Regional Lab, Makkah. Saudi Arabia

Khalid Alquthami (Correspondence) Regional Lab, Makkah. Saudi Arabia 1 Regional Lab, Makkah. Saudi Arabia stract: Clinical specificity and genotype/subtype detection of viruses using the Cobas TaqScreen MPX system V 2.0, which is a nucleic acid test (NAT) that uses multiples

More information

L 256/32 Official Journal of the European Union

L 256/32 Official Journal of the European Union L 256/32 Official Journal of the European Union 1.10.2005 COMMISSION DIRECTIVE 2005/61/EC of 30 September 2005 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards

More information

Achieving Consensus on Increased Risk Donors to Improve Access to Organ Transplantation Executive Summary

Achieving Consensus on Increased Risk Donors to Improve Access to Organ Transplantation Executive Summary Achieving Consensus on Increased Risk Donors to Improve Access to Organ Transplantation Executive Summary Introduction To address the current shortage of organs for transplantation, (114,651 candidates

More information

ARBOVIRAL RISKS TO BLOOD SAFETY IN AUSTRALIA. Clive Seed Australian Red Cross Blood Service ISBT TTD-WP meeting 26 June, 2015

ARBOVIRAL RISKS TO BLOOD SAFETY IN AUSTRALIA. Clive Seed Australian Red Cross Blood Service ISBT TTD-WP meeting 26 June, 2015 ARBOVIRAL RISKS TO BLOOD SAFETY IN AUSTRALIA Clive Seed Australian Red Cross Blood Service ISBT TTD-WP meeting 26 June, 2015 Transfusion significant arboviral threats Dengue - epidemic Ross River virus

More information

Hepa%%s E Virus Is it a Concern?

Hepa%%s E Virus Is it a Concern? IPFA/PEI 17 th Workshop on Surveillance and Screening of Blood Borne Pathogens 26-27 May 2010, The Regent Esplanade Zagreb Hotel, Zagreb, Croa%a Hepa%%s E Virus Is it a Concern? Keiji Matsubayashi Hokkaido

More information

Hepatitis is an epidemic disease that can be caused by different viruses including hepatitis viruses A, B, C, D or E.

Hepatitis is an epidemic disease that can be caused by different viruses including hepatitis viruses A, B, C, D or E. What is Hepatitis? Hepatitis is an epidemic disease that can be caused by different viruses including hepatitis viruses A, B, C, D or E. Hepatitis A and E are not chronic and are mostly present in areas

More information

Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey

Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey This questionnaire consists of three sections: A. Collection and

More information

UvA-DARE (Digital Academic Repository) Residual infectious risks in blood transfusion Lieshout-Krikke, R.W. Link to publication

UvA-DARE (Digital Academic Repository) Residual infectious risks in blood transfusion Lieshout-Krikke, R.W. Link to publication UvA-DARE (Digital Academic Repository) Residual infectious risks in blood transfusion Lieshout-Krikke, R.W. Link to publication Citation for published version (APA): Lieshout-Krikke, R. W. (2016). Residual

More information

Routine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors

Routine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors Journal of the Egyptian Society of Haematology & Research, Vol. 7, No. 2, September: 1-5, 2011 Routine Use of Mini-Pool Nucleic Acid Testing (MP-NAT) Multiplex Assay for Sero-Negative Blood Donors HISHAM

More information

Transfusion transmitted infections in National Haemovigilance Systems: the Greek experience

Transfusion transmitted infections in National Haemovigilance Systems: the Greek experience Transfusion transmitted infections in National Haemovigilance Systems: the Greek experience Global blood product safety 10 April 2019, Rome, Italy Constantina Politis National Coordinating Haemovigilance

More information

Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid Amplification Testing

Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid Amplification Testing The new england journal of medicine original article Detection of HIV-1 and HCV Infections among Antibody-Negative Blood Donors by Nucleic Acid Amplification Testing Susan L. Stramer, Ph.D., Simone A.

More information

Source of effectiveness data Effectiveness data were derived from a single study combined with a review of previously completed studies.

Source of effectiveness data Effectiveness data were derived from a single study combined with a review of previously completed studies. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection Busch M P, Korelitz J J, Kleinman S H, Lee S R, Aubuchon J P, Schreiber

More information

INITIAL EVALUATION AND MANAGEMENT FOLLOWING EXPOSURE TO BLOOD OR BODY FLUIDS

INITIAL EVALUATION AND MANAGEMENT FOLLOWING EXPOSURE TO BLOOD OR BODY FLUIDS Page 1 of 11 Original Date of Issue: June 1991 Reviewed 2/96 5/97 11/98 11/99 5/01 5/02 12/05 Revised 9/95 5/97 5/00 7/02 3/06 6/08 6/10 The following are the procedures to be followed when a person sustains

More information

Diagnosis of Acute HCV Infection

Diagnosis of Acute HCV Infection Hepatitis C Online PDF created December 20, 2017, 7:54 pm Diagnosis of Acute HCV Infection This is a PDF version of the following document: Module 1: Screening and Diagnosis of Hepatitis C Infection Lesson

More information

Sensitivity of the Procleix HIV-1/HCV Assay for Detection of Human Immunodeficiency Virus Type 1 and Hepatitis C Virus RNA in a High-Risk Population

Sensitivity of the Procleix HIV-1/HCV Assay for Detection of Human Immunodeficiency Virus Type 1 and Hepatitis C Virus RNA in a High-Risk Population JOURNAL OF CLINICAL MICROBIOLOGY, July 2002, p. 2387 2391 Vol. 40, No. 7 0095-1137/02/$04.00 0 DOI: 10.1128/JCM.40.7.2387 2391.2002 Copyright 2002, American Society for Microbiology. All Rights Reserved.

More information

Interventions for Babesia (and Plasmodium)

Interventions for Babesia (and Plasmodium) Interventions for Babesia (and Plasmodium) Susan L. Stramer, Ph.D. May 16 2017 www.aabb.org Babesiosis Malaria-like illness caused by Babesia spp. Asymptomatic fatal Non-specific symptoms (malaise, fever,

More information

U.S. changes in Kidney Allocation

U.S. changes in Kidney Allocation U.S. changes in Kidney Allocation Match kidneys with longest survival to patients with longest survival No parallel matching for kidneys with lower survival potential Decrease discard of kidneys with lower

More information

ANNALS OF HEALTH LAW Advance Directive VOLUME 23 SPRING 2014 PAGES

ANNALS OF HEALTH LAW Advance Directive VOLUME 23 SPRING 2014 PAGES ANNALS OF HEALTH LAW Advance Directive VOLUME 23 SPRING 2014 PAGES 101-112 United States Blood Donor Policy on Gay Men: Adopting an Italian Individual Risk Assessment Policy Melissa Kong* I. INTRODUCTION

More information

20. HIV and AIDS. Objectives. How is HIV transmitted?

20. HIV and AIDS. Objectives. How is HIV transmitted? 20. HIV and AIDS Objectives By the end of this session, group members will be able to: Explain what HIV and AIDS are. Describe how HIV is transmitted. Explain the difference between HIV and AIDS. List

More information

Professor Adrian Mindel

Professor Adrian Mindel Causes of genital ulceration viruses and others Professor Adrian Mindel University of Sydney VIM 16 th August 2012 Outline Definition Causes Epidemiology Diagnosis Definition of genital ulcer A defect

More information

Transplants. Mickey B. C. Koh

Transplants. Mickey B. C. Koh Transfusion in Stem Cell Transplants Mickey B. C. Koh Director: Stem Cell Transplant Programme Department of Haematology, St. George s Hospital and Medical School, London, UK Medical Director: Cell Therapy

More information

Overview of Organ Donation and Transplantation

Overview of Organ Donation and Transplantation 2 Overview of Organ Donation and Transplantation Overview of Organ Donation and Transplantation A summary of organ donation and transplantation activity in the UK during the financial year from April 207

More information

2017 CST-Astellas Canadian Transplant Fellows Symposium. Optimizing use of organs from Increased Risk Donors

2017 CST-Astellas Canadian Transplant Fellows Symposium. Optimizing use of organs from Increased Risk Donors 2017 CST-Astellas Canadian Transplant Fellows Symposium Optimizing use of organs from Increased Risk Donors Atual Humar, MD Atul Humar is a Professor in the Department of Medicine, University of Toronto.

More information

PUBLICATION OF THE SUPERIOR HEALTH COUNCIL No. 9291

PUBLICATION OF THE SUPERIOR HEALTH COUNCIL No. 9291 PUBLICATION OF THE SUPERIOR HEALTH COUNCIL No. 9291 Sexual risk behaviour and blood donation Part I: Blood donations by MSM This version was validated by the Board on October 2016 1 This advisory report

More information

HIV Lecture. Anucha Apisarnthanarak, MD Division of Infectious Diseases Thammasart University Hospital

HIV Lecture. Anucha Apisarnthanarak, MD Division of Infectious Diseases Thammasart University Hospital HIV Lecture Anucha Apisarnthanarak, MD Division of Infectious Diseases Thammasart University Hospital End-2001 global estimates for children and adults People living with HIV/AIDS New HIV infections in

More information